CDC anthrax vaccine safety & efficacy research program: interim report
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Washington, DC
National Academy Press
[2001]
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Title from PDF t.p. - "Prepublication Copy, Uncorrected Proofs" --PDF t.p Description based on version viewed December 23, 2014 Paralleltitel: CDC anthrax vaccine safety and efficacy research program |
| Beschreibung: | 1 online resource (1 PDF file (xii, 45 pages)) illustrations |
| ISBN: | 0309579872 9780309579872 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043038239 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151120s2001 |||| o||u| ||||||eng d | ||
| 020 | |a 0309579872 |c electronic bk. |9 0-309-57987-2 | ||
| 020 | |a 9780309579872 |c electronic bk. |9 978-0-309-57987-2 | ||
| 035 | |a (OCoLC)229431501 | ||
| 035 | |a (DE-599)BVBBV043038239 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 616.956 |2 22 | |
| 245 | 1 | 0 | |a CDC anthrax vaccine safety & efficacy research program |b interim report |c Institute of Medicine |
| 246 | 1 | 3 | |a CDC anthrax vaccine safety and efficacy research program |
| 264 | 1 | |a Washington, DC |b National Academy Press |c [2001] | |
| 300 | |a 1 online resource (1 PDF file (xii, 45 pages)) |b illustrations | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Title from PDF t.p. - "Prepublication Copy, Uncorrected Proofs" --PDF t.p | ||
| 500 | |a Description based on version viewed December 23, 2014 | ||
| 500 | |a Paralleltitel: CDC anthrax vaccine safety and efficacy research program | ||
| 505 | 8 | |a Anthrax in its inhalational form is a deadly but very rare manifestation of infection with a common organism, Bacillus anthracis. Anthrax spores are very stable, a characteristic that makes possible their delivery as a weapon of biological warfare, and examples of weapons development efforts using anthrax are well known. It is important to protect the men and women in our armed services to the greatest extent possible. The Department of Defense (DoD) established the Anthrax Vaccine Immunization Program (AVIP) in order to do so; however, some parties have raised questions about the safety and even the efficacy of the vaccine. As a result, the DoD is sponsoring an Institute of Medicine (IOM) study of the safety and efficacy of the vaccine, and Congress has instructed the Centers for Disease Control and Prevention (CDC) to conduct further safety and efficacy research. The CDC contracted with the IOM to review their research program for completeness and appropriateness. This document is an interim report of the Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, and reflects only a preliminary review of a program still in development | |
| 610 | 1 | 4 | |a Centers for Disease Control and Prevention (U.S.) |
| 650 | 4 | |a Anthrax / prevention & control / United States | |
| 650 | 4 | |a Anthrax Vaccines / United States | |
| 650 | 4 | |a Drug Evaluation / United States | |
| 650 | 4 | |a Program Evaluation / United States | |
| 650 | 7 | |a MEDICAL / Infectious Diseases |2 bisacsh | |
| 650 | 7 | |a HEALTH & FITNESS / Diseases / Contagious |2 bisacsh | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Anthrax |x Vaccination | |
| 650 | 4 | |a Vaccines |x Effectiveness | |
| 650 | 4 | |a Vaccines |x Safety measures | |
| 651 | 4 | |a USA | |
| 710 | 2 | |a Institute of Medicine (U.S.) |b Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123516 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028462886 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123516 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123516 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175400019951616 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043038239 |
| collection | ZDB-4-EBA |
| contents | Anthrax in its inhalational form is a deadly but very rare manifestation of infection with a common organism, Bacillus anthracis. Anthrax spores are very stable, a characteristic that makes possible their delivery as a weapon of biological warfare, and examples of weapons development efforts using anthrax are well known. It is important to protect the men and women in our armed services to the greatest extent possible. The Department of Defense (DoD) established the Anthrax Vaccine Immunization Program (AVIP) in order to do so; however, some parties have raised questions about the safety and even the efficacy of the vaccine. As a result, the DoD is sponsoring an Institute of Medicine (IOM) study of the safety and efficacy of the vaccine, and Congress has instructed the Centers for Disease Control and Prevention (CDC) to conduct further safety and efficacy research. The CDC contracted with the IOM to review their research program for completeness and appropriateness. This document is an interim report of the Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, and reflects only a preliminary review of a program still in development |
| ctrlnum | (OCoLC)229431501 (DE-599)BVBBV043038239 |
| dewey-full | 616.956 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.956 |
| dewey-search | 616.956 |
| dewey-sort | 3616.956 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03572nmm a2200529zc 4500</leader><controlfield tag="001">BV043038239</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151120s2001 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309579872</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-309-57987-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309579872</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-309-57987-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)229431501</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043038239</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.956</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CDC anthrax vaccine safety & efficacy research program</subfield><subfield code="b">interim report</subfield><subfield code="c">Institute of Medicine</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">CDC anthrax vaccine safety and efficacy research program</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, DC</subfield><subfield code="b">National Academy Press</subfield><subfield code="c">[2001]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (1 PDF file (xii, 45 pages))</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from PDF t.p. - "Prepublication Copy, Uncorrected Proofs" --PDF t.p</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on version viewed December 23, 2014</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Paralleltitel: CDC anthrax vaccine safety and efficacy research program</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Anthrax in its inhalational form is a deadly but very rare manifestation of infection with a common organism, Bacillus anthracis. Anthrax spores are very stable, a characteristic that makes possible their delivery as a weapon of biological warfare, and examples of weapons development efforts using anthrax are well known. It is important to protect the men and women in our armed services to the greatest extent possible. The Department of Defense (DoD) established the Anthrax Vaccine Immunization Program (AVIP) in order to do so; however, some parties have raised questions about the safety and even the efficacy of the vaccine. As a result, the DoD is sponsoring an Institute of Medicine (IOM) study of the safety and efficacy of the vaccine, and Congress has instructed the Centers for Disease Control and Prevention (CDC) to conduct further safety and efficacy research. The CDC contracted with the IOM to review their research program for completeness and appropriateness. This document is an interim report of the Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, and reflects only a preliminary review of a program still in development</subfield></datafield><datafield tag="610" ind1="1" ind2="4"><subfield code="a">Centers for Disease Control and Prevention (U.S.)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anthrax / prevention & control / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anthrax Vaccines / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Program Evaluation / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Infectious Diseases</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Diseases / Contagious</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anthrax</subfield><subfield code="x">Vaccination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vaccines</subfield><subfield code="x">Effectiveness</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vaccines</subfield><subfield code="x">Safety measures</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123516</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028462886</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123516</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123516</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043038239 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:15:41Z |
| institution | BVB |
| isbn | 0309579872 9780309579872 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028462886 |
| oclc_num | 229431501 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 online resource (1 PDF file (xii, 45 pages)) illustrations |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2001 |
| publishDateSearch | 2001 |
| publishDateSort | 2001 |
| publisher | National Academy Press |
| record_format | marc |
| spelling | CDC anthrax vaccine safety & efficacy research program interim report Institute of Medicine CDC anthrax vaccine safety and efficacy research program Washington, DC National Academy Press [2001] 1 online resource (1 PDF file (xii, 45 pages)) illustrations txt rdacontent c rdamedia cr rdacarrier Title from PDF t.p. - "Prepublication Copy, Uncorrected Proofs" --PDF t.p Description based on version viewed December 23, 2014 Paralleltitel: CDC anthrax vaccine safety and efficacy research program Anthrax in its inhalational form is a deadly but very rare manifestation of infection with a common organism, Bacillus anthracis. Anthrax spores are very stable, a characteristic that makes possible their delivery as a weapon of biological warfare, and examples of weapons development efforts using anthrax are well known. It is important to protect the men and women in our armed services to the greatest extent possible. The Department of Defense (DoD) established the Anthrax Vaccine Immunization Program (AVIP) in order to do so; however, some parties have raised questions about the safety and even the efficacy of the vaccine. As a result, the DoD is sponsoring an Institute of Medicine (IOM) study of the safety and efficacy of the vaccine, and Congress has instructed the Centers for Disease Control and Prevention (CDC) to conduct further safety and efficacy research. The CDC contracted with the IOM to review their research program for completeness and appropriateness. This document is an interim report of the Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, and reflects only a preliminary review of a program still in development Centers for Disease Control and Prevention (U.S.) Anthrax / prevention & control / United States Anthrax Vaccines / United States Drug Evaluation / United States Program Evaluation / United States MEDICAL / Infectious Diseases bisacsh HEALTH & FITNESS / Diseases / Contagious bisacsh Medizin Anthrax Vaccination Vaccines Effectiveness Vaccines Safety measures USA Institute of Medicine (U.S.) Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program Sonstige oth http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123516 Aggregator Volltext |
| spellingShingle | CDC anthrax vaccine safety & efficacy research program interim report Anthrax in its inhalational form is a deadly but very rare manifestation of infection with a common organism, Bacillus anthracis. Anthrax spores are very stable, a characteristic that makes possible their delivery as a weapon of biological warfare, and examples of weapons development efforts using anthrax are well known. It is important to protect the men and women in our armed services to the greatest extent possible. The Department of Defense (DoD) established the Anthrax Vaccine Immunization Program (AVIP) in order to do so; however, some parties have raised questions about the safety and even the efficacy of the vaccine. As a result, the DoD is sponsoring an Institute of Medicine (IOM) study of the safety and efficacy of the vaccine, and Congress has instructed the Centers for Disease Control and Prevention (CDC) to conduct further safety and efficacy research. The CDC contracted with the IOM to review their research program for completeness and appropriateness. This document is an interim report of the Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, and reflects only a preliminary review of a program still in development Centers for Disease Control and Prevention (U.S.) Anthrax / prevention & control / United States Anthrax Vaccines / United States Drug Evaluation / United States Program Evaluation / United States MEDICAL / Infectious Diseases bisacsh HEALTH & FITNESS / Diseases / Contagious bisacsh Medizin Anthrax Vaccination Vaccines Effectiveness Vaccines Safety measures |
| title | CDC anthrax vaccine safety & efficacy research program interim report |
| title_alt | CDC anthrax vaccine safety and efficacy research program |
| title_auth | CDC anthrax vaccine safety & efficacy research program interim report |
| title_exact_search | CDC anthrax vaccine safety & efficacy research program interim report |
| title_full | CDC anthrax vaccine safety & efficacy research program interim report Institute of Medicine |
| title_fullStr | CDC anthrax vaccine safety & efficacy research program interim report Institute of Medicine |
| title_full_unstemmed | CDC anthrax vaccine safety & efficacy research program interim report Institute of Medicine |
| title_short | CDC anthrax vaccine safety & efficacy research program |
| title_sort | cdc anthrax vaccine safety efficacy research program interim report |
| title_sub | interim report |
| topic | Centers for Disease Control and Prevention (U.S.) Anthrax / prevention & control / United States Anthrax Vaccines / United States Drug Evaluation / United States Program Evaluation / United States MEDICAL / Infectious Diseases bisacsh HEALTH & FITNESS / Diseases / Contagious bisacsh Medizin Anthrax Vaccination Vaccines Effectiveness Vaccines Safety measures |
| topic_facet | Centers for Disease Control and Prevention (U.S.) Anthrax / prevention & control / United States Anthrax Vaccines / United States Drug Evaluation / United States Program Evaluation / United States MEDICAL / Infectious Diseases HEALTH & FITNESS / Diseases / Contagious Medizin Anthrax Vaccination Vaccines Effectiveness Vaccines Safety measures USA |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123516 |
| work_keys_str_mv | AT instituteofmedicineuscommitteetoreviewthecdcanthraxvaccinesafetyandefficacyresearchprogram cdcanthraxvaccinesafetyefficacyresearchprograminterimreport AT instituteofmedicineuscommitteetoreviewthecdcanthraxvaccinesafetyandefficacyresearchprogram cdcanthraxvaccinesafetyandefficacyresearchprogram |